Safety and Effectiveness of Genomic Biomarker-Guided Neoadjuvant Treatments for Advanced and Oligometastatic Prostate Cancer
Led by The First Affiliated Hospital of Xiamen University · Updated on 2024-04-26
40
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of neoadjuvant therapy guided by genomic biomarkers for men with locally advanced and oligometastatic prostate cancer. This phase 2 study aims to tailor treatment based on each patients tumor genetic profile to better understand how these therapies work before surgery.
Participants will be assigned to one of four treatment groups based on their genomic profile. Each group receives a combination of rezvilutamide, androgen deprivation therapy ADT, and one additional drug docetaxel, pamiparib, cisplatin, or tislelizumab. Treatments are given over about 24 weeks, followed by imaging to assess response and then radical prostatectomy plus pelvic lymph node dissection. The study will also analyze tissue and survival outcomes after surgery.
During the study, participants will undergo genetic testing, imaging scans including PSMA PETCT, and various laboratory tests. Researchers will monitor clinical and pathological responses at 20 and 24 weeks, including rates of complete response and minimal residual disease. Longer-term follow-up will assess progression-free and overall survival for up to three years. Safety and tolerability will be closely observed throughout the treatment and surgery periods.
CONDITIONS
Brief Title
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
Research Team
K
Kaiyan Zhang, M.D.
H
Haichao Huang, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
The First Affiliated Hospital of Xiamen University
Lead Sponsor
Who Can Participate
Age: 18Years +
MALE
Eligibility Criteria
You may qualify if you...
Male aged 18 years or older
Able to provide informed consent according to local regulations
Imaging confirmed locally advanced (cT3b to cT4, N0 to N1, M0) or oligometastatic prostate cancer with no visceral metastasis and 5 or fewer bone metastases
Suitable for radical prostatectomy and pelvic lymph node dissection after neoadjuvant therapy and consent to surgery
Histologically confirmed prostate adenocarcinoma without small cell or neuroendocrine differentiation
ECOG performance status 0 or 1 with life expectancy of 3 years or more
Adequate organ function based on laboratory tests performed within 4 weeks before enrollment
Consent to genetic testing prior to enrollment
No prior systemic or localized prostate cancer treatment except up to 28 days of certain hormone therapies
Ability to swallow oral medication and comply with study procedures
Consent to use reliable contraception and avoid sperm donation during and for 3 months after treatment
No contraindications to study drug treatments
You will not qualify if you...
History of hypersensitivity to any study drugs
More than 28 days of prior hormone therapy or participation in other therapeutic clinical trials within 28 days before enrollment
Prior local treatment of primary or metastatic prostate cancer lesions
Prior bilateral orchiectomy
Severe androgen deficiency with testosterone more than 50 ng/dL below normal range
History of brain metastases or epilepsy
Severe cardiovascular disease including recent myocardial infarction, unstable angina, certain heart failure, prolonged QT interval, or uncontrolled hypertension
Significant digestive tract abnormalities affecting drug intake or absorption
Other serious co-morbidities that may interfere with treatment or surgery
Other active cancers requiring treatment or malignancies within 5 years
Surgery other than diagnostic prostate biopsy within 4 weeks before enrollment
Active HIV with detectable viral load, active hepatitis B or C unless treated and undetectable
History of non-compliance or unsuitable for study participation or surgery after neoadjuvant therapy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 20 to 24 weeks
Participants receive genomic biomarker-guided neoadjuvant drug therapy according to assigned group for locally advanced or oligometastatic prostate cancer.
Infusion and oral medication visits every 3 or 4 weeks, depending on assigned therapy, for up to 6 cycles or 24 weeks
Surgery
Duration - Single surgical procedure
Participants undergo radical prostatectomy plus pelvic lymph node dissection after completing neoadjuvant therapy.
1 visit (in-person) for surgery
Post-operative Follow-up
Duration - Up to 3 years
Participants are followed for histopathological evaluation and survival monitoring after surgery.
Periodic visits for clinical assessments over 3 years
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Comparing Moderate External Beam Radiotherapy with Ultra Hypofractionation and Brachytherapy for Treating Low Volume Oligometastatic Prostate Cancer in Men
Improving Radiotherapy for Intermediate and High-Risk Prostate Cancer with Focal Boost and Shorter Treatment Schedules
Phase 2 Study of SBRT with Zimberelimab, Etrumadenant, and Quemliclustat for Men with Hormone Sensitive Oligometastatic Prostate Cancer
A Randomized Phase III Trial Comparing Comprehensive Radiotherapy with Primary Tumor Radiotherapy in Men Aged 18 to 85 with Oligometastatic Prostate Cancer
Safety and Effectiveness of Genomic Biomarker-Guided Neoadjuvant Treatments for Advanced and Oligometastatic Prostate Cancer
New Robotic Surgery Technique for Treating Advanced Prostate Cancer
Preserving Bladder Support to Improve Recovery and Urinary Control
Phase II Trial of Lutetium-177 PSMA with Stereotactic Ablative Radiotherapy for Men with Oligometastatic Prostate Cancer
Apatamide With Maximal Tumor Removal for Oligometastatic Prostate Cancer
A Randomized Controlled Trial of Combined Treatment Approaches
Study of Neoadjuvant Intense Endocrine Therapy Before Prostatectomy in High Risk and Locally Advanced Prostate Cancer
Observational Registry on Outcomes After Definitive Prostate and Metastasis-Directed Radiotherapy for Men with Synchronous Oligometastatic Prostate Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial.